The MyRealWorld MG study, a longitudinal digital observational study exploring the impact of myasthenia gravis (MG) from the patient perspective, has been run by Vitaccess on behalf of argenx since December 2019. Since then, over 2,400 adults with MG residing across 10 countries have been recruited to contribute data on their condition and its impact on their lives, via a series of custom surveys and validated patient-reported outcomes instruments on the MyRealWorld MG study app.Â
We are pleased to announce that the role of sponsor has now been transferred from argenx to Vitaccess following the mutual decision, with support from the multi-stakeholder scientific advisory board (SAB), to continue collecting valuable real-world data on MG while running the study under a new syndicated framework. Via this framework, Vitaccess is providing the opportunity for novel research initiatives using the anonymized study dataset, including extended commercial subscriptions. The governance (including the role of the SAB) of the study and what is expected of participants is unchanged.Â
For more information on the MyRealWorld MG study or research opportunities using the study dataset, please contact us at mg@vitaccess.com. For access to the study’s published manuscripts, conference posters, and white paper, please visit our Publications page and click on or scroll down to “Myasthenia Gravis”.Â
